Crystal Structure, Epitope, and Functional Impact of an Antibody Against a Superactive FVIIa Provide Insights into Allosteric Mechanism

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2019 Jul 12

PMID 31294329

Citations 1

Authors

Longguang Jiang

Xie Xie

Jinyu Li

Egon Persson

Mingdong Huang

Affiliations

Soon will be listed here.

Abstract

Background: Blood coagulation factor VIIa (FVIIa) plays its critical physiological role in the initiation of hemostasis. Even so, recombinant FVIIa is successfully used as a bypassing agent for factor VIII or IX in the treatment of bleeds in patients with severe hemophilia with inhibitors. To investigate the utility of more potent FVIIa variants with enhanced intrinsic activity, molecules such as V21D/E154V/M156Q-FVIIa (FVIIa) were designed.

Methods: Surface plasmon resonance was used to characterize the binding of mAb4F5 to FVIIa and related variants. X-ray crystallography was used to determine the structure of the Fab fragment of mAb4F5 (Fab4F5). Molecular docking and small angle X-ray scattering led to a model of FVIIa:Fab4F5 complex.

Results: The binding experiments, functional effects on FVIIa and structure of mAb4F5 (originally intended for quantification of FVIIa in samples containing FVII(a)) pinpointed the epitope (crucial role for residue Asp21) and shed light on the role of the N-terminus of the protease domain in FVIIa allostery. The potential antigen-combining sites are composed of 1 hydrophobic and 1 negatively charged pocket formed by 6 complementarity-determining region (CDR) loops. Structural analysis of Fab4F5 shows that the epitope interacts with the periphery of the hydrophobic pocket and provides insights into the molecular basis of mAb4F5 recognition and tight binding of FVIIa.

Conclusion: The binary complex explains and supports the selectivity and functional consequences of Fab4F5 association with FVIIa and illustrates the potentially unique antigenicity of this FVIIa variant. This will be useful in the design of less immunogenic variants.

Citing Articles

Crystal structure, epitope, and functional impact of an antibody against a superactive FVIIa provide insights into allosteric mechanism.

Jiang L, Xie X, Li J, Persson E, Huang M Res Pract Thromb Haemost. 2019; 3(3):412-419.

PMID: 31294329 PMC: 6611371. DOI: 10.1002/rth2.12211.

References

Brunger A . Version 1.2 of the Crystallography and NMR system. Nat Protoc. 2007; 2(11):2728-33. DOI: 10.1038/nprot.2007.406. View

Rasmussen S, Choi H, Rosenbaum D, Kobilka T, Thian F, Edwards P . Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature. 2007; 450(7168):383-7. DOI: 10.1038/nature06325. View

Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, Engler J . Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol. 2003; 334(4):733-49. DOI: 10.1016/j.jmb.2003.10.007. View

Banner D, Darcy A, Chene C, Winkler F, Guha A, Konigsberg W . The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996; 380(6569):41-6. DOI: 10.1038/380041a0. View

Lentz S, Ehrenforth S, Abdul Karim F, Matsushita T, Weldingh K, Windyga J . Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014; 12(8):1244-53. PMC: 4238784. DOI: 10.1111/jth.12634. View

Jiang L, Botkjaer K, Andersen L, Yuan C, Andreasen P, Huang M . Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem J. 2012; 449(1):161-6. DOI: 10.1042/BJ20121132. View

Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

Collis A, Brouwer A, Martin A . Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol. 2002; 325(2):337-54. DOI: 10.1016/s0022-2836(02)01222-6. View

Persson E, Kjalke M, Olsen O . Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A. 2001; 98(24):13583-8. PMC: 61084. DOI: 10.1073/pnas.241339498. View

10.

Franke D, Svergun D . , a program for rapid shape determination in small-angle scattering. J Appl Crystallogr. 2016; 42(Pt 2):342-346. PMC: 5023043. DOI: 10.1107/S0021889809000338. View

11.

Oomen C, Hoogerhout P, Kuipers B, Vidarsson G, van Alphen L, Gros P . Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design. J Mol Biol. 2005; 351(5):1070-80. DOI: 10.1016/j.jmb.2005.06.061. View

12.

Fellouse F, Wiesmann C, Sidhu S . Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A. 2004; 101(34):12467-72. PMC: 515084. DOI: 10.1073/pnas.0401786101. View

13.

Persson E, Olsen O, Bjorn S, Ezban M . Vatreptacog alfa from conception to clinical proof of concept. Semin Thromb Hemost. 2012; 38(3):274-81. DOI: 10.1055/s-0032-1302442. View

14.

. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 5):760-3. DOI: 10.1107/S0907444994003112. View

15.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

16.

Sorensen B, Persson E, Freskgard P, Kjalke M, Ezban M, Williams T . Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem. 1997; 272(18):11863-8. DOI: 10.1074/jbc.272.18.11863. View

17.

Otwinowski Z, Minor W . Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26. DOI: 10.1016/S0076-6879(97)76066-X. View

18.

Jiang L, Xie X, Li J, Persson E, Huang M . Crystal structure, epitope, and functional impact of an antibody against a superactive FVIIa provide insights into allosteric mechanism. Res Pract Thromb Haemost. 2019; 3(3):412-419. PMC: 6611371. DOI: 10.1002/rth2.12211. View

19.

Mian I, Bradwell A, Olson A . Structure, function and properties of antibody binding sites. J Mol Biol. 1991; 217(1):133-51. DOI: 10.1016/0022-2836(91)90617-f. View

20.

Mahlangu J, Weldingh K, Lentz S, Kaicker S, Karim F, Matsushita T . Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015; 13(11):1989-98. DOI: 10.1111/jth.13141. View